This application requests funding for a CCSG grant for the University of Colorado Cancer Center (UCCC) for years 09-13. The University of Colorado Cancer Center is a """"""""Center"""""""" within the School of medicine at the University of Colorado Health Sciences Center. The Cancer Center goals are; 1) to contribute through coordinated research, clinical, prevention and control and educational activities effort to the eventual elimination of cancer as a human health problem, and 2) to provide the citizens of the State of Colorado and the Rocky Mountains region with state of the art cancer research, therapy, prevention, control and educational programs. The Cancer Center serves more than 6 million people in Colorado and the 7 surrounding states in the Rocky Mountain region. The over 280 Cancer Center members have more than $48 million (annual direct costs) in peer- reviewed grants an contracts relating to the cancer problem. Cancer Center members provide care to 15-20% of the cancer population in the region and enter more than 1,600 patients on cancer clinical trials each year. The Cancer Center enters an increasing number of patients of clinical trials emphasizing novel trials of the Center and high priority trials of the National Cancer Institute. The majority of cancer educational, prevention and control programs in the region are organized by Cancer Center members. The Center provides the major centralized support for these functions through its 11 shared """"""""core"""""""" facilities in Biostatistics, Clinical Investigations, Cytogenetics, Fermentation, Flow Cytometry, Histopathology/Tissue Procurement, Laboratory Animals/Transgenic Animals, Macromolecular Resources, Radiological Sciences, Immunology and Tissue Culture/Monoclonal Antibodies. The Cancer Center has 14 institutional members including the Health Sciences Center schools, affiliated hospitals and other institutions with a primary focus in cancer. The chief executive officers of these organizations form the Cancer Center Board which assures coordination of the cancer effort in the region. The Cancer Center has four major program divisions: Basic Research, Clinical Activities, Education and prevention and Control and is developing a Community Research Division. The Basic Research Division is divided into: Immunology; Molecular Biology; Growth Regulation; Cell Surface; Hormones an Cancer; Chromosomes and Mutation. The Clinical Division is divided into: Adult Clinical Oncology, Breast Cancer, Lung Cancer and Pediatric oncology; and the Prevention and Control Division is divided into Causation and Clinical Prevention and Control programs. The UCCC is currently an NCI designated """"""""Clinical Cancer Center"""""""". Our plans are to seek approval as an """"""""NCI Comprehensive Cancer Center"""""""" during the next funding cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-12S2
Application #
6135216
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Ciolino, Henry P
Project Start
1988-03-01
Project End
2001-01-31
Budget Start
1999-02-17
Budget End
2000-01-31
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Radakovich, Lauren B; Marolf, Angela J; Shannon, John P et al. (2018) Development of a microcomputed tomography scoring system to characterize disease progression in the Hartley guinea pig model of spontaneous osteoarthritis. Connect Tissue Res 59:523-533
Wu, Xiaorong; An, Xiuxiang; Zhang, Caiguo et al. (2018) Clb6-Cdc28 Promotes Ribonucleotide Reductase Subcellular Redistribution during S Phase. Mol Cell Biol 38:

Showing the most recent 10 out of 1634 publications